

October 25, 2011
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

Results of Third Party Allocation of New Shares

The Company has received notice from the underwriter, Mitsubishi UFJ Morgan Stanley, that it will not exercise an over-allotment option in connection with the equity offering which was approved by the Board of Directors on September 14 and 29, 2011. As a result, the Company has announced that it will not issue new shares for the equity offering at this time.

The Company held an equity offering of 765,000 common shares by over-allotment underwritten by Mitsubishi UFJ Morgan Stanley including the public offering with its listing on the Osaka Securities Exchange JASDAQ Growth Market. This allocation of new shares to a third party relates to the equity offering by over-allotment for the purpose of returning common shares borrowed from Mr. Yoshida, CEO.

<Note>

(1)	Equity offering by over-allotment	765,000 common shares
(2)	Amount to be paid per share	391 JPY
(3)	Total amount to be paid	299,115,000 JPY
(4)	Allotment price per share	515.20 JPY
(5)	Total amount to be allotted	394,128,000 JPY
(6)	Increase in capital stock per share	257.60 JPY
	Increase in capital reserve per share	257.60 JPY
(7)	Allotment entity	Mitsubishi UFJ Morgan Stanley
(8)	Unit of shares	100 shares
(9)	Application due	November 17, 2011
(10)	Payment due	November 18, 2011

[Contact]

Hiroki Maekawa
Board Director, Corporate Officer, Chief Financial Officer
Tel: +081(0)3 5472 1125